FDA Approves Talazoparib in BRCA+ Breast Cancer
Compared with standard chemotherapy, the PARP inhibitor extended progression-free survival for patients with advanced BCRA-positive breast cancer. FDA Approvals …read more
Miami OBGYN Society
A Membership Organization of South Florida Obstetrician-Gynecologists
